For personal use only

ASX Announcement

8 April 2026

OSPREY Registry Data Accepted for Oral Presentation at European Society of Gastrointestinal Endoscopy Days 2026

Highlights

- OSPREY registry interim data accepted for oral presentation at ESGE Days 2026
- Registry data to be presented by Dr Enrique Vazquez-Sequeiros (University Hospital Ramón y Cajal, Madrid, Spain)
- Oral presentation scheduled for 14 May 2026 in Milan, Italy
- Data demonstrate encouraging survival outcomes and favourable safety profile in real-world clinical practice

Sydney, Australia – 8 April 2026: OncoSil Medical Limited (ASX: OSL) ("OncoSil Medical" or "the Company"), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce that its abstract featuring interim data from the OSPREY registry has been accepted for presentation at European Society of Gastrointestinal Endoscopy (ESGE) Days 2026. The data will be presented by Dr Enrique Vazquez-Sequeiros (University Hospital Ramón y Cajal, Madrid, Spain) on 14 May 2026 at the ESGE Days congress in Milan, Italy.

This follows the Company's earlier announcement (3 December 2025) regarding the submission of OSPREY interim data to the congress and represents an important milestone in the clinical and scientific validation of the OncoSil™ device.

OSPREY is a post-market, multi-centre, observational, prospective registry in which data is recorded from patients with unresectable LAPC receiving gemcitabine-based chemotherapy who have undergone EUS-guided implantation of the OncoSil™ device as part of their routine clinical care. Enrolment commenced in April 2022 and is ongoing at participating centres.

The accepted abstract for the presentation to be delivered by Dr Enrique Vazquez-Sequeiros is titled:

"**OSPREY Registry: First Interim Analysis of Patients with Unresectable Locally Advanced Pancreatic Cancer Treated with EUS-Guided Phosphorus-32 Microparticles plus Gemcitabine-Based Chemotherapy in Routine Clinical Practice**"

Interim results from the OSPREY registry (n=64) demonstrate a favourable safety profile and encouraging efficacy outcomes in patients with unresectable locally advanced pancreatic cancer treated with OncoSil™ in addition to chemotherapy. Key highlights in the data to be presented include:

For personal use only

- The majority of patients (75%) were treated in the first-line setting, with median overall survival ranging from 20.6 to 22.0 months from the time of diagnosis in these cohorts.
- The Local Disease Control Rate at 12 weeks post-implant was high at 91.4% in first-line patients, and 7 patients proceeded to curative-intent surgical resection.
- Safety outcomes were favourable, with 15.6% of patients reporting only mild, transient adverse device effects and no serious complications, pancreatitis, or hospitalisations observed.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"We are delighted that the OSPREY data has been accepted for presentation at ESGE Days 2026. This recognition at a leading global endoscopy congress underscores the growing clinical interest in OncoSil™ and its potential to improve outcomes for patients with unresectable locally advanced pancreatic cancer. We look forward to sharing these important data with the international medical community."

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 96424981	**Mr. Tim Luscombe** Company Secretary E: tim.luscombe@bio101.com T: +61 429 707 079	**Ms. Julia Maguire** **The Capital Network** Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year[1]. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. https://gco.iarc.fr/en